Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Debio 4126 + Octreotide acetate |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Debio 4126 | Debio-4126|Debio4126 | Debio 4126 comprises the somatostatin analog octreotide formulated for sustained release, which potentially activates somatostatin receptors leading to decreased angiogenesis and tumor cell proliferation, and increased tumor cell death (NCI Drug Dictionary). | ||
Octreotide acetate | Sandostatin Lar Depot | SMS 201-995 | Sandostatin Lar Depot (octreotide acetate) mimics the activity of somatostatin, which may control the growth of neuroendocrine tumors (PMID: 26605828). Sandostatin Lar Depot (octreotide acetate) is FDA approved for symptom control in patients with carcinoid tumors and VIPomas (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05364944 | Phase I | Debio 4126 + Lanreotide acetate Debio 4126 + Octreotide acetate | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01) | Active, not recruiting | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | 0 |